Pancreatic ductal adenocarcinoma

This early-phase study tests a personalized mRNA cancer vaccine (XH001) given alongside standard treatment after surgery for people with high-risk solid tumors (bile duct, gallbladder, pancreatic, liver, or stomach cancer). The main goals are to check safety and see if the vaccin…

This phase II trial is testing whether the drug olaparib can help prevent pancreatic cancer from coming back in people who have already had surgery and chemotherapy and carry a BRCA1, BRCA2, or PALB2 mutation. Olaparib is a targeted therapy that blocks a repair enzyme cancer cell…

This early-stage trial tests a drug called samuraciclib in 15 people with localized pancreatic cancer that can be surgically removed. Participants will take the drug for about two weeks before their planned surgery. Researchers will check safety and look for changes in tumor cell…

This phase 2 trial is testing whether adding an investigational drug called telisotuzumab adizutecan to standard chemotherapy can help people with pancreatobiliary cancers, including pancreatic ductal adenocarcinoma. Participants will receive either the new combination or standar…

This phase 2 trial is testing a chemotherapy combination called NALIRIFOX given before surgery to people with borderline resectable pancreatic cancer. The goal is to shrink the tumor enough to allow successful removal and reduce the chance of the cancer coming back. The study wil…

This study tests an experimental drug called BLU-924 (SAR449336) in people with advanced pancreatic, lung, or colorectal cancers that have specific KRAS mutations. The drug is designed to block the cancer-driving KRAS protein. The trial will enroll about 265 participants to evalu…

This phase 2 study tests an experimental drug called BT5528 in adults with metastatic pancreatic cancer that has spread and worsened after one prior treatment. The drug targets a specific protein on cancer cells. Researchers will measure how well it shrinks tumors and track side …

This study tests an experimental oral drug, BPI-572270, in 120 adults with advanced solid tumors (lung, colorectal, or pancreatic cancer) that have specific RAS gene mutations. The trial has two phases: first to find a safe dose and check for side effects, then to see if the drug…

This Phase 3 trial tests whether adding an experimental oral drug called atebimetinib to a modified chemotherapy regimen helps people with metastatic pancreatic cancer live longer. About 510 adults who have not had prior treatment will receive either the new combination or standa…

This phase 2 trial tests whether giving a powerful chemotherapy regimen called NALIRIFOX along with targeted radiation and the drug capecitabine can shrink pancreatic tumors enough to allow successful surgery. The study enrolls 60 people with borderline resectable or locally adva…

This study is testing a new biologic drug called sacituzumab tirumotecan (MK-2870), alone or with chemotherapy, in people with advanced colorectal, pancreatic, or biliary tract cancers that cannot be removed by surgery. The main goals are to check safety and see if tumors shrink.…

This early-phase trial is testing a new oral drug called RMC-5127, alone or combined with other drugs, in adults with advanced solid tumors that have a specific KRAS G12V mutation. The study includes people with lung, colorectal, and pancreatic cancers who have already tried stan…

This study tests an experimental oral drug called S241656 (BDTX-4933) in people with advanced solid tumors that have certain genetic changes (KRAS, BRAF, or other RAS/MAPK mutations). The trial has two parts: first, finding a safe dose, then testing how well it works alone or wit…

Researchers are testing an experimental injectable drug called XNW28012 in people with metastatic pancreatic cancer that has worsened after two standard chemotherapy regimens. The phase III trial plans to enroll 226 adults and randomly assigns them in a 2:1 ratio to receive eithe…

This study tests a new drug called daraxonrasib in people with pancreatic cancer who have already had surgery and chemotherapy. The goal is to see if taking the drug can delay or prevent the cancer from returning compared to just watching and waiting. About 500 adults will be ran…

This Phase 3 trial is testing whether adding a new targeted pill (INCB161734) to standard chemotherapy helps people with a specific type of advanced pancreatic cancer (KRAS G12D mutation) live longer. About 588 participants who have not had prior treatment for metastatic disease …

This phase 3 trial tests a new drug called daraxonrasib, taken as a pill, either alone or with standard chemotherapy, against chemotherapy alone for people with metastatic pancreatic cancer. About 900 adults with confirmed pancreatic cancer that has spread will be randomly assign…

This pilot study looks at whether closely monitoring and managing blood sugar levels can help people with pancreatic cancer. About 50 participants will wear a continuous glucose monitor during chemotherapy. Half will get intensive glucose management from an endocrinologist, while…

This early-phase trial tests a new drug called ASP2138, which helps the immune system attack cancer cells that have a specific marker (CLDN18.2). It is for people with advanced stomach, gastroesophageal junction (GEJ), or pancreatic cancer that cannot be removed by surgery or has…

Researchers are testing whether giving chemotherapy before surgery helps people with clearly resectable pancreatic head cancer or periampullary cancer live longer than going straight to surgery. The trial enrolls 262 participants and randomly assigns them to either mFOLFIRINOX ch…

This early-phase trial tests a drug called TTI-101 combined with a precise type of radiation (SBRT) in 18 people with pancreatic cancer that is borderline resectable or locally advanced. The goal is to see if the combination is safe and can improve how long patients live without …

Pancreatic ductal adenocarcinoma often returns near where it started, even after surgery. This study tests whether a more thorough operation, called total mesopancreatic excision, can improve local disease control and survival. During pancreaticoduodenectomy, surgeons remove the …

Researchers are testing two investigational radiopharmaceuticals in adults with advanced solid tumors, including colorectal, pancreatic, biliary tract, gastric, esophageal, and head and neck cancers. First, participants receive SKL35502, an imaging agent that highlights tumors ca…

This study tests whether adding an experimental drug called zoldonrasib to standard chemotherapy helps people with a specific genetic form of metastatic pancreatic cancer (KRAS G12D mutation) live longer without their cancer growing. About 670 adults with advanced pancreatic canc…

This early-stage trial tests a new drug called M7437 in people with advanced solid tumors that have not responded to standard treatments. M7437 is an antibody-drug conjugate designed to deliver chemotherapy directly to cancer cells that have a specific marker (Ly6E). The study ai…

This early-stage study is testing a new drug called M0324, a bispecific antibody designed to target cancer cells. The trial will look at M0324 alone, with the immunotherapy pembrolizumab, and with chemotherapy in about 77 people with advanced solid tumors that have not responded …

This phase 3 trial compares a combination of two experimental oral drugs, zoldonrasib and daraxonrasib, against standard chemotherapy (gemcitabine plus nab-paclitaxel) as the first treatment for people with metastatic pancreatic cancer that has a specific KRAS G12D mutation. The …

This early-phase study tests a new treatment for people with advanced pancreatic cancer that has spread and has a specific mutation called KRAS G12D. The treatment uses tiny particles called exosomes to deliver a molecule that blocks the mutated gene. The goal is to find the best…

This study tests a new oral drug, VS-7375, alone or with another drug (cetuximab), in 180 people with metastatic pancreatic cancer that has a specific genetic change called KRAS G12D. The goal is to see if the drug shrinks tumors and is safe. Participants must have this mutation …

This early-phase trial tests a new drug called PTM-101 given alongside standard chemotherapy for people with pancreatic cancer that is either borderline resectable or locally advanced (meaning it has not spread far but is hard to remove surgically). The goal is to see if adding P…

This early-phase trial tests an experimental drug called ASP2138 in 25 adults with resectable pancreatic cancer whose tumors have a specific protein (CLDN18.2). Participants receive ASP2138 two weeks before surgery, then standard chemotherapy after surgery. The main goal is to ch…

This early-phase study tests a new drug called DSB2455 in adults with advanced cancers (breast, ovarian, prostate, pancreatic, or brain metastases) that have a specific DNA repair problem. The main goals are to check safety and see if the drug shrinks tumors. About 180 participan…

This large Phase 2/3 trial is testing whether adding an investigational drug called telisotuzumab adizutecan to standard chemotherapy (FOLFOX) can help people with metastatic pancreatic cancer live longer or shrink their tumors. About 900 participants will be randomly assigned to…

This phase 3 trial tests whether adding setidegrasib (ASP3082) to standard chemotherapy helps people with a specific KRAS G12D mutation in metastatic pancreatic cancer live longer. About 614 adults will be randomly assigned to receive either setidegrasib or a placebo, along with …

This early-phase study tests a new drug called STRO-004 in adults with advanced solid tumors that have not responded to standard treatments. The study has three parts: finding a safe dose of STRO-004 alone, testing that dose in more patients, and combining STRO-004 with another d…

This study tests a new drug called BNT329 in people with advanced solid tumors that have a specific marker (CA19-9). The main goals are to check safety and find the best dose. About 245 participants will take part. The drug works by targeting cancer cells and may help control tum…

This phase III trial tests whether a genetic signature can guide chemotherapy choice after surgery for pancreatic cancer. Patients are randomly assigned to receive either oxaliplatin-based or gemcitabine-based chemotherapy, chosen either by standard clinical criteria or by a tran…

This study tests a new drug called JAB-23E73, which targets KRAS gene changes, combined with two standard chemotherapies (nab-paclitaxel and gemcitabine) in people whose pancreatic cancer has spread and who haven't had prior treatment. The goal is to see if the combination is saf…

This early-stage trial is testing whether a personalized vaccine made from a patient's own immune cells, combined with standard chemotherapy, is safe and feasible for treating pancreatic cancer after surgical removal. The vaccine is designed to train the immune system to recogniz…

This phase 2 trial is testing whether adding an experimental drug called HRS-4642 to standard immunotherapy and chemotherapy can help people with pancreatic cancer. The study includes adults with borderline resectable, locally advanced, or metastatic pancreatic cancer. Researcher…

This study tests a drug called tegavivint in children, teens, and young adults whose solid tumors have come back or stopped responding to treatment. The goal is to find the safest dose and see if it can shrink tumors by blocking a key growth signal inside cancer cells. About 147 …

This phase III trial tests whether giving a higher dose of radiation can help people with locally advanced pancreatic cancer live longer. Participants must have already had 4-6 months of chemotherapy. The study compares higher-dose radiation to standard care (more chemo, observat…

This early-phase study tests a new drug, LY3962673, in people with advanced solid tumors that have a specific KRAS G12D mutation, including pancreatic, lung, and colorectal cancers. The main goals are to check safety and see if the drug shrinks tumors, given alone or with chemoth…

This early-phase trial tests an investigational drug called ABBV-400 in about 300 adults with advanced solid tumors, including liver, pancreatic, breast, and ovarian cancers. The study aims to see if the drug can shrink tumors and to check for side effects. Participants receive A…

This study tests whether adding a heat-based treatment called radiofrequency ablation (RFA) to a standard procedure (ERCP) can help people with advanced pancreatic cancer that has spread to the liver live longer. About 178 adults with limited liver spread will be randomly assigne…

This early-stage trial tests a new type of immunotherapy where a patient's own T cells are genetically engineered to recognize and attack cancer cells with a specific KRAS G12D mutation. The study includes adults with advanced lung, colorectal, pancreatic, or endometrial cancers …

This phase 2 trial is testing whether combining targeted radiation therapy with two immune-boosting drugs can help people with metastatic pancreatic ductal adenocarcinoma. The study enrolls adults whose cancer has progressed after at least one line of standard treatment. Particip…

This study tests whether adding the drug BMS-986504 to standard chemotherapy can help control pancreatic cancer in people with a specific genetic change (MTAP deletion). About 60 adults with this type of pancreatic cancer will receive the combination before and after surgery or w…

This early-phase trial tests a new drug called AB801, which blocks a protein (AXL) that helps cancers grow and resist treatment. It is given alongside chemotherapy and immunotherapy to people with bile duct or pancreatic cancer that is either borderline resectable, locally advanc…

This early-phase trial tests whether adding pegcetacoplan to standard chemotherapy (mFOLFIRINOX) is safe and effective for people with metastatic pancreatic cancer. Pegcetacoplan targets part of the immune system to possibly slow tumor growth and reduce blood clots, a common comp…

This early-stage trial tests a new treatment for people with advanced pancreatic cancer that cannot be removed by surgery. The therapy uses a light-sensitive drug and a special light delivered through a thin tube into the blood vessels feeding the tumor. The goal is to see if it …

This study tests whether adding the drug relacorilant to standard chemotherapy can help people with metastatic pancreatic cancer live longer without their disease getting worse. About 60 adults who have not yet been treated for advanced pancreatic cancer will receive the combinat…

This early-phase trial tests a drug called XER-001 (a form of amifostine given through a tube into the small intestine) combined with precise radiation therapy for people with locally advanced pancreatic cancer that cannot be removed by surgery. The study will enroll 36 participa…

This early-stage trial tests a new drug called YL211 in 155 people with advanced solid tumors who have no standard treatment options left. The study has three parts: first, finding a safe dose; then, confirming that dose; and finally, testing how well it works. The main goals are…

This early-phase trial is testing whether combining two experimental drugs, JAB-21822 and JAB-3312, can safely shrink or control advanced solid tumors that carry a specific KRAS G12C mutation. The study includes people with cancers like non-small cell lung, colorectal, or pancrea…

This study looks at whether removing the entire pancreas is better than removing just part of it for people with certain cancers in the head of the pancreas who are at high risk of complications. The main goal is to see if total removal helps patients live longer without hurting …

This trial tests an experimental oral drug called TT-702 in people with advanced solid tumors. The drug works by blocking a protein that tumors use to hide from the immune system. The study aims to find the safest dose of TT-702 when given alone and in combination with an immunot…

This study tests a new drug (HRS-4642) combined with standard chemotherapy (nab-paclitaxel and gemcitabine) in 30 people with locally advanced pancreatic cancer that has a specific gene change (KRAS G12D). The goal is to shrink tumors enough to allow surgery. Participants will ha…

This study is testing a new way to find and treat several types of advanced solid tumors, including kidney, pancreatic, and colorectal cancers. It uses a special radioactive compound that attaches to a protein found on these cancer cells. The study has multiple parts: first, to s…

This phase 2 trial is testing whether giving two different chemotherapy regimens one after the other can shrink pancreatic tumors that are borderline or locally advanced, making them easier to remove surgically. The study enrolls 64 adults with pancreatic adenocarcinoma. Particip…

This early-stage trial tests a new drug called PHN-012 in people with advanced colon, pancreatic, or lung cancer that has stopped responding to standard treatments. The drug is an antibody-drug conjugate, designed to deliver a powerful cancer-killing agent directly to tumor cells…

This study tests a new way of giving chemotherapy to people with pancreatic cancer that is on the edge of being removable. The goal is to shrink the tumor enough for successful surgery. About 35 adults will receive two different chemo drug combinations in alternating cycles. The …

This early-stage trial is testing an experimental immunotherapy called AB122, given alone or combined with other investigational drugs, in people with advanced solid tumors such as pancreatic, colorectal, lung, and stomach cancers. The goal is to find out which combinations are s…

This early-phase trial tests a new therapy called GC203 TIL, which uses a patient's own immune cells that are genetically modified to better attack pancreatic cancer. Ten adults whose cancer has not responded to standard treatments will receive these cells after a short course of…

This study tests a new drug called ASP3082 in 60 people with advanced lung or pancreatic cancer that has a specific gene change (KRAS G12D). Participants receive the drug intravenously once a week in 21-day cycles. The main goal is to see how well the drug shrinks tumors and to u…

This phase II trial is testing whether giving the immunotherapy drug pembrolizumab (Keytruda) along with standard FOLFIRINOX chemotherapy before surgery can help shrink tumors in people with resectable pancreatic cancer. The study enrolls adults with localized, potentially resect…

This study tests two experimental drugs, elironrasib and daraxonrasib, given alone or together, in people with advanced solid tumors that have a specific KRAS G12C mutation. The goal is to see if the drugs are safe and can shrink or control the cancer. About 534 adults with lung,…

This early-stage study tests a cancer vaccine that targets a common mutated protein (KRAS) combined with two immunotherapy drugs (balstilimab and botensilimab) in people with advanced colorectal or pancreatic cancer that has spread. The goal is to see if the combination can shrin…

This study tests an experimental drug called ART0380, taken as a pill, in people with advanced or metastatic solid tumors (cancers that have spread). The drug targets a protein that helps cancer cells repair their DNA. Researchers want to find the safest dose when given alone or …

This early-stage trial is testing a new type of targeted radiation therapy for people with advanced pancreatic, lung, breast, or colorectal cancers. The treatment uses a radioactive drug that seeks out cancer cells to deliver radiation directly, aiming to kill them while sparing …

This study tests a new drug called AZD0901, alone or with other cancer treatments, in people with advanced solid tumors that have a specific protein called CLDN18.2. The goal is to see if the drug is safe and can shrink tumors. About 224 adults with stomach, pancreatic, or bile d…

This trial is testing whether combining standard chemotherapy with a procedure that uses heat to destroy cancer cells can shrink pancreatic tumors before surgery. The approach uses an endoscope guided by ultrasound to deliver radiofrequency ablation directly to the tumor. Researc…

This study is testing several new experimental drugs (RAS(ON) inhibitors) combined with standard chemotherapy or other targeted therapies in people with advanced colorectal or pancreatic cancer that has spread. The goal is to see if these combinations are safe and can shrink tumo…

This early-stage trial is testing an experimental drug called BMS-986488, alone or combined with other cancer drugs, in people with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety and find the right dose. About 437 adults w…

This study tests a new drug called BNT327 combined with standard chemotherapy in adults with metastatic pancreatic cancer that has not been treated before. The goal is to see if the combination shrinks tumors better than chemo alone. About 105 participants will be enrolled, and r…

This study tests a new biologic drug called ANO31905 combined with standard chemotherapy as a first treatment for people with advanced pancreatic cancer that has a specific marker (CLDN18.2). The trial has two phases: first to find a safe dose, then to see if the combination shri…

This trial tests whether a virus called VCN-01, given more frequently, is safe and tolerable when combined with standard chemotherapy (nab-paclitaxel and gemcitabine) for people with newly diagnosed stage IV pancreatic cancer that has spread. Participants receive up to three dose…

This phase 3 trial tests whether a multi-disciplinary treatment plan can help people with pancreatic cancer that has spread to only a few other places in the body live longer without the disease getting worse. About 80 adults with this condition will receive either standard care …

This study follows about 70 people with metastatic pancreatic cancer who are receiving NalIriFOx as their first treatment. Researchers are collecting real-world data to see how well the drug combination controls the disease and what side effects occur. The goal is to understand w…

This study tests a drug called 177Lu-FAP-2286, which delivers radiation directly to cancer cells. It is for people with advanced solid tumors (like pancreatic, lung, or breast cancer) that have a specific protein called FAP. The trial has two parts: Phase 1 finds the safest dose,…

This early-phase study tests a new oral drug called MOMA-313, alone or with another drug (olaparib), in people with advanced solid tumors that have certain DNA repair flaws. The main goals are to check safety and find the right dose. About 220 adults with cancers like prostate, p…

This early-stage trial is testing a new drug called IBI3028 in people with advanced solid tumors that cannot be removed by surgery or have spread. The drug works by attaching to two proteins (EGFR and c-Met) found on some cancer cells and delivering two anti-cancer agents directl…

This treatment program tests a personalized cell therapy for people with advanced pancreatic or colorectal cancers that have a specific genetic mutation (KRAS G12D). Patients' own immune cells are collected, genetically engineered to recognize and attack the cancer, and then infu…

This early-phase study tests an experimental drug called PF-08046050 in adults with advanced solid tumors (like lung, colon, or stomach cancer) that have come back or not improved with standard treatments. The drug is designed to stick to cancer cells and kill them. The main goal…

This trial tests SPEDOX-6, a version of the chemotherapy drug doxorubicin wrapped in a protein shell, in people with advanced solid tumors such as soft-tissue sarcoma, triple-negative breast cancer, non-small cell lung cancer, cervical cancer, ovarian cancer, and certain pancreat…

This study tests a new drug called Spevatamig (PT886) in people with advanced stomach, pancreatic, or bile duct cancers that have spread or cannot be removed by surgery. The drug is a type of antibody that targets two proteins on cancer cells to help the immune system attack them…

This trial tests whether a short course of focused radiation followed by chemotherapy (nab-paclitaxel and gemcitabine) plus the immunotherapy drug camrelizumab can shrink borderline or locally advanced pancreatic tumors enough to allow complete surgical removal. The study enrolls…

This study tests a new drug that delivers a tiny dose of radiation directly to cancer cells that have a specific marker called FAP. The trial involves 112 adults with advanced cancers of the pancreas, stomach, esophagus, colon, ovary, head/neck, sarcoma, or mesothelioma. First, a…

This early-phase trial is testing an experimental oral drug called KST-6051 in adults with advanced or metastatic solid tumors that have a KRAS mutation, including certain lung, pancreatic, and colorectal cancers. The main goal is to check the drug's safety and how the body proce…

This early-stage trial is testing whether adding an experimental cancer vaccine (ELI-002 7P) and an immunotherapy drug (tislelizumab) to standard chemotherapy (mFOLFIRINOX) is safe and effective for people with a specific type of pancreatic cancer that has a KRAS mutation. The st…

This study explores whether growing miniature versions of a patient's own pancreatic tumor in the lab (called organoids) can help doctors choose the most effective drug for that individual. About 25 adults with advanced, inoperable pancreatic cancer will have their tumor organoid…

This early-stage trial tests whether injecting an immune-boosting drug (mitazalimab) directly into the tumor during a special electrical ablation procedure (IRE) is safe for people with locally advanced pancreatic cancer. The goal is to see if this approach can strengthen the bod…

This phase 2 trial is testing whether giving two immunotherapy drugs, durvalumab and oleclumab, before surgery can boost the immune system's attack on pancreatic cancer. The study involves people with resectable pancreatic ductal adenocarcinoma (PDAC) who will receive the drugs i…

This early-stage trial is testing a new radioactive drug (177Lu-DFC413) to see if it is safe and can shrink tumors in people with advanced solid cancers like pancreatic, lung, breast, colorectal, and sarcoma. About 180 adults whose cancer has progressed after standard treatments …

This early-phase study tests a new radioactive drug called NRT6008, given alongside standard chemotherapy, for people with advanced pancreatic cancer that cannot be removed by surgery or has spread to nearby lymph nodes. The trial will enroll 58 adults to find the safest dose and…

This Phase 2 trial tests a combination of two immunotherapy drugs, odetiglucan and mitazalimab, as a maintenance treatment for people with unresectable pancreatic cancer that has not worsened after 4-8 months of standard chemotherapy. The study will enroll 100 adults and measure …

This early-phase trial tests an oral drug called ALTA3263 in about 448 adults with advanced solid tumors (like pancreatic, lung, or colorectal cancer) that have a KRAS mutation. The main goals are to check safety, find the right dose, and see how the body processes the drug. Part…

This early-stage trial tests a new therapy that takes a patient's own immune T-cells, engineers them to recognize and attack pancreatic cancer cells with specific KRAS mutations, and infuses them back. The study includes 96 adults with advanced pancreatic cancer who have the righ…

This phase 2 trial tests whether adding the immunotherapy drug cemiplimab to standard chemotherapy gemcitabine can help people with a certain genetic type of advanced pancreatic cancer live longer. The study enrolls 43 adults whose cancer has spread and who have already tried one…

This early-stage trial tests a new drug called KO-2806, alone or with other cancer drugs, in adults with advanced solid tumors that have not responded to standard treatments. The study aims to find safe doses and check for early signs of tumor shrinkage. About 300 participants wi…

This early-phase study tests a new gene therapy for people with pancreatic cancer that has returned after standard treatment. The therapy uses a patient's own immune cells, modified to target a protein called B7-H3 on cancer cells, and includes a safety switch to control side eff…

This phase 3 trial tests whether adding radiotherapy to standard chemotherapy after pancreatic cancer surgery can prevent the cancer from coming back. It enrolls 288 high-risk patients who have had surgery but still have factors like positive margins or lymph node involvement. Pa…

This early-phase trial is testing a new type of cell therapy for people with advanced pancreatic cancer that has spread or cannot be removed by surgery. The treatment uses specially engineered natural killer (NK) cells that target two proteins found on cancer cells. Up to 42 part…

This early-phase study tests a new drug called BBO-11818 in people with advanced cancers that have a KRAS mutation, including lung, pancreatic, and colorectal cancers. The main goals are to check safety and find the best dose, while also seeing if the drug can shrink tumors. Abou…

This early-phase trial tests a new drug called AVA6103 in 174 people with advanced solid tumors (like pancreatic, stomach, or lung cancer) that have not responded to standard treatments. The drug is designed to activate only inside tumors, potentially killing cancer cells while r…

This phase 2 study tests a new drug called IBI343 combined with two chemotherapy drugs (gemcitabine and nab-paclitaxel) in people with advanced stomach, gastroesophageal junction, or pancreatic cancers that have a specific protein (CLDN18.2). The goal is to see if the combination…

This early-phase trial tests a new way to deliver chemotherapy directly to the lining of the abdomen in people with pancreatic cancer that has spread there. The treatment, called PIPAC, uses a spray of chemotherapy drugs under pressure to reach tumor spots more effectively. The s…

This study tests an experimental drug called RMC-9805, taken as a pill, in adults with advanced solid tumors (such as lung, colorectal, or pancreatic cancer) that have a specific mutation in the KRAS gene called G12D. The drug is given alone or in combination with another oral dr…

This program offers a personalized vaccine called PCNAT-01 to patients with pancreatic cancer who have had surgery and finished chemotherapy. The vaccine is made from each patient's unique tumor proteins and is given as shots to train the immune system to fight any remaining canc…

This early-phase study tests a new drug called CT3001 in people with advanced solid tumors (like colorectal or pancreatic cancer) that have stopped responding to standard treatments. The study has two parts: first, finding a safe dose of CT3001 alone, then testing it combined wit…

This Phase 3 trial tests whether a new combination of drugs—TQB2868 (a dual antibody) plus anlotinib capsules—works better than standard chemotherapy for people with metastatic pancreatic cancer that has spread. About 566 participants will be randomly assigned to receive either t…

This study tests a new drug called BMS-986523, alone or with other cancer drugs, in people with advanced solid tumors (like lung, colorectal, or pancreatic cancer) that have a specific genetic change (KRAS mutation). The goal is to see if it is safe and works. About 252 adults wi…

This phase 2 trial is testing whether adding the experimental drug HRS-4642 to standard chemotherapy (gemcitabine and albumin-bound paclitaxel) can help shrink pancreatic tumors before surgery and prevent recurrence afterward. About 30 adults with resectable or borderline resecta…

This phase 2 trial is testing a combination of four drugs (HRS-4642, gemcitabine, albumin-bound paclitaxel, and adebrelimab) as treatment for pancreatic cancer before and after surgery. The goal is to see if this approach is safe and effective at shrinking tumors and improving su…

This study tests a new drug called MR001 combined with standard chemotherapy for people with advanced pancreatic cancer that has worsened after initial treatment. The goal is to find a safe dose and see if the combination can shrink tumors or slow the disease. About 45 adults wit…

This study tests a new drug (HRS-4642) combined with an immunotherapy (adebrelimab) and possibly other cancer drugs for people with advanced pancreatic cancer that has not responded to standard treatments. The goal is to find safe doses and see if the combination can shrink tumor…

This study tests two new drug combinations (DB-1311 with BNT327 or DB-1305) in 450 adults with advanced or metastatic solid tumors that have not responded to other treatments. The main goals are to check safety and see if tumors shrink. Participants must be in fairly good health …

This study tests whether adding a targeted drug called panitumumab to standard chemotherapy helps people with a specific type of advanced pancreatic cancer (KRAS wild-type) live longer. About 94 adults whose cancer has spread or can't be removed will be randomly assigned to get c…

This study tests whether adding two new drugs (zimberelimab and quemliclustat) to standard chemotherapy can help shrink pancreatic tumors that are either borderline removable or have spread locally. About 56 adults with untreated pancreatic cancer will receive the combination. Th…

This early-stage trial tests an experimental drug called KQB548 in people with advanced solid tumors (like pancreatic, colorectal, or lung cancer) that have a specific KRAS G12D mutation. The main goals are to find a safe dose and see if the drug can shrink tumors. About 78 parti…

This study tests a new experimental drug called mavrostobart (PT199) in people with advanced solid tumors, specifically non-small cell lung cancer and pancreatic cancer. The drug is given alone or combined with other cancer treatments. The goal is to find the safest dose and see …

This early-phase trial is testing an experimental drug called DA-3501 in 51 adults with advanced stomach, gastro-esophageal junction, or pancreatic cancers that have a specific protein (CLDN18.2). Participants receive the drug by IV once every three weeks. The main goals are to f…

This study tests a mix of chemotherapy (NALIRIFOX), an immunotherapy drug (adebrelimab), and a special type of radiation (PULSAR) as a first treatment for people with advanced pancreatic cancer that cannot be removed by surgery. The goal is to see if this combination is safe and …

This study is for people with metastatic pancreatic cancer that has worsened after initial treatment. It tests a new drug, ONT01, combined with standard chemotherapy (gemcitabine and nab-paclitaxel) to see if it can reprogram immune cells in the tumor to fight cancer better. Abou…

This study tests a new treatment called KSQ-004EX for people with advanced solid tumors that have not responded to standard therapies. The treatment uses a patient's own immune cells (tumor infiltrating lymphocytes) that are genetically modified to be more powerful against cancer…

This early-phase trial is testing a new drug called ASP5834 in people with advanced solid tumors that have certain changes in the KRAS gene. The study will first find a safe dose of ASP5834 given alone or with another drug (panitumumab) in people with colorectal cancer. Up to 364…

This study tests a new oral drug, TNG462, combined with other treatments for people with pancreatic or non-small cell lung cancer that has lost the MTAP gene and, in some cases, has a RAS mutation. The trial has two phases: first to find the safest dose, then to see how well the …

This study tests whether injecting gadolinium-based nanoparticles (AGuIX) before precise MR-guided radiation can improve tumor control for people with centrally located lung tumors or locally advanced pancreatic cancer. About 100 participants will receive the nanoparticle injecti…

This early-phase study tests whether tamoxifen, a drug commonly used for breast cancer, can shrink or stabilize pre-cancerous pancreatic cysts in women. The goal is to see if taking tamoxifen for up to 24 weeks can delay or eliminate the need for surgery. The study will enroll 15…

This study is testing an experimental oral drug called RMC-6236 in adults with advanced solid tumors (like lung, colorectal, or pancreatic cancer) that have specific RAS mutations. The main goals are to find safe doses and understand side effects. About 754 participants will take…

This study compares two chemotherapy regimens for people with advanced pancreatic cancer that has spread or cannot be removed by surgery. One group gets NALIRIFOX (a mix of four drugs) every two weeks, while the other gets a modified version of gemcitabine, nab-paclitaxel, and ci…

This early-phase study tests a new drug called IBI343 in people with advanced solid tumors that cannot be removed by surgery or have spread. The main goals are to check safety, find the best dose, and see if the drug can shrink tumors. About 470 participants will take part in mul…

This phase 2 trial tests a new drug called NC410 combined with standard chemotherapy (FOLFIRINOX) and immunotherapy drugs (nivolumab with or without ipilimumab) in 20 people with metastatic pancreatic cancer who have not had prior treatment. The main goal is to check safety and i…

This study tests whether adding targeted radiation therapy (SBRT) to standard care helps people with pancreatic cancer that has returned only in the original area live longer and feel better. About 174 adults whose cancer came back locally after surgery will be randomly assigned …

This early-phase trial tests whether adding an experimental MK2 inhibitor (zunsemetinib) to standard chemotherapy (mFOLFIRINOX) can better control metastatic pancreatic cancer. About 51 adults who have not had prior treatment for advanced disease will participate. The main goals …

This study tests a new daily pill, VS-7375, in people with advanced solid tumors (like pancreatic, lung, or colorectal cancer) that have a specific KRAS G12D mutation. The goal is to see if the drug is safe and can shrink tumors when used alone or with other cancer treatments. Ab…

This study tests whether giving a combination of three chemotherapy drugs (gemcitabine, cisplatin, and nab-paclitaxel) before surgery can help shrink pancreatic tumors and improve outcomes. It includes 36 adults with pancreatic cancer that is either removable or borderline remova…

This trial tests whether removing both the main pancreatic tumor and small spots in the liver or lungs after chemotherapy can help patients. It includes 40 people whose cancer has spread to only a few spots. Everyone gets the same treatment: chemo first, then surgery if the cance…

This phase 2 trial tests whether adding valproic acid and simvastatin to standard chemotherapy can help people with untreated metastatic pancreatic cancer live longer without their disease getting worse. About 240 participants will be randomly assigned to receive either the stand…

This early-phase trial is testing whether adding two experimental drugs (KN510 and KN713) to standard chemotherapy (mFOLFIRINOX) is safe and effective for people with advanced pancreatic cancer that cannot be removed by surgery. About 30 adults aged 19–75 who have not had prior c…

This early-phase trial tests whether adding leflunomide, a drug used for rheumatoid arthritis, to standard chemotherapy (gemcitabine) is safe for people with advanced pancreatic cancer that cannot be removed by surgery. About 19 participants will receive the combination to find t…

This study tests a new drug called JPI-547, taken as a pill, together with standard chemotherapy for people with advanced pancreatic cancer that cannot be removed by surgery. The goal is to find the safest dose and see if the combination helps shrink tumors or slow the disease. A…

This early-phase trial is testing whether adding the drug fostamatinib to standard chemotherapy can help people with resectable pancreatic cancer. Fostamatinib is already approved for a blood disorder but has not been tried in pancreatic cancer. The study will enroll 36 participa…

This early-phase trial is testing a new antibody drug called ZM008, first by itself and then together with another drug (toripalimab), in people with advanced solid tumors like lung, head and neck, and pancreatic cancers. The study aims to find a safe dose and see if the combinat…

This early study tests a device called Suizenji that uses focused ultrasound waves to heat and destroy pancreatic cancer cells from outside the body. It is for 10 adults with advanced pancreatic cancer that cannot be removed by surgery. The goal is to see if the treatment is safe…

This study tests whether adding Acoustic Cluster Therapy (ACT) to standard chemotherapy can shrink inoperable pancreatic tumors. About 25 adults with locally advanced pancreatic cancer will receive both treatments. The goal is to see if the combination improves response rates and…

This study tests whether a major surgery that removes the pancreatic tumor and all visible cancer in the abdomen, followed by pumping heated chemotherapy drugs directly into the belly, is safe for people with pancreatic cancer that has spread to the lining of the abdomen. Twenty …

This study is testing a procedure called EUS-guided radiofrequency ablation (RFA) for people with pancreatic tumors who are not candidates for surgery. The procedure uses a thin needle passed through an endoscope to deliver heat directly to the tumor. Researchers want to see if i…

This early-phase trial tests a new drug called VVD-159642, which targets specific cancer-driving proteins. It is given alone or with other drugs (sotorasib or trametinib) to people with advanced solid tumors that have certain genetic changes. The main goals are to check safety, f…

This early-stage trial tests a new type of immunotherapy for people with advanced pancreatic cancer that has spread or cannot be removed. The treatment uses specially engineered natural killer (NK) cells that target two cancer-related proteins at once. Up to 42 participants will …

This phase 2 trial tests a new approach for people with metastatic pancreatic cancer: alternating two standard chemotherapy regimens every month instead of using just one. The goal is to see if this switching strategy can keep the cancer from growing for at least 6 months. About …

This study tests whether adding a medical glue (Glubran 2) to the surgical connection in the pancreas can prevent a serious complication called pancreatic fistula, which is a leak of digestive fluids. About 100 adults undergoing pancreas removal for cancer will be randomly assign…

This study tests a new drug called ABSK141 in people with advanced solid tumors that have a specific gene change called KRAS G12D. The goal is to find a safe dose and see if the drug can shrink tumors. About 401 adults with cancers like colorectal, lung, or pancreatic cancer will…

This early-stage study tests an experimental drug called TJ033721 (givastomig) in people with advanced or metastatic solid tumors that have stopped responding to standard treatments. The main goals are to check the drug's safety, find the right dose, and see how the body processe…

This study tests a new oral drug called JYP0015 in people with advanced solid tumors (such as pancreatic, lung, or colorectal cancer) that have a RAS mutation. The drug aims to block the activity of the mutated RAS protein, which drives cancer growth. The trial will enroll 210 pa…

This large Phase 3 trial tests whether adding two immune-boosting drugs (ivonescimab and AK117) to standard chemotherapy helps people with metastatic pancreatic cancer live longer. About 999 participants will be randomly assigned to get the new drugs or a placebo, all with chemo.…

This study tests whether combining two drugs, AK130 and AK112, can help control advanced pancreatic cancer. About 160 adults whose cancer has worsened after up to two prior treatments will receive the combination or AK112 alone. The goal is to see if the treatment shrinks tumors …

This phase 2 trial tests whether adding drugs that block the tumor's immune-evasion pathways to standard radiation and immunotherapy can boost the body's immune attack on pancreatic cancer before surgery. About 60 patients with advanced pancreatic cancer who are candidates for su…

This study tests two drugs, IN10018 and RNK08954, given together to people with advanced solid tumors that have a specific genetic change called KRAS G12D. The goal is to find the best dose and see if the combination can shrink tumors. About 92 adults with locally advanced or met…

This study tests whether adding specially designed nanocells (tiny particles that deliver a potent drug directly to cancer cells) to standard chemotherapy can help people with metastatic pancreatic cancer live longer. About 144 adults whose cancer has worsened despite prior treat…

This study tests an experimental drug called AZD5863 in adults with advanced stomach, gastro-esophageal junction, pancreatic, or esophageal cancers that have spread. The drug is a bispecific antibody designed to bring immune cells close to cancer cells to attack them. The main go…

This study tests a new approach using immune cells from healthy donors, engineered to recognize and attack cancer cells. The target is chosen based on each participant's tumor profile. The trial includes 85 adults with advanced solid tumors that have not responded to standard tre…

This study tests a new drug called MBRC-201 in people with advanced solid tumors (prostate, breast, colorectal, lung, or pancreatic cancer) that have not responded to standard treatments. The drug is an antibody-drug conjugate, designed to deliver a cancer-killing agent directly …

This early study tests a new device called YntraDose™ that delivers a single dose of radiation directly into pancreatic tumors that cannot be removed by surgery. Ten participants will receive the implant along with standard chemotherapy. The main goals are to see if the procedure…

This early-phase trial tests whether adding chemotherapy directly into the abdomen (intraperitoneal paclitaxel) to standard IV chemotherapy (NALIRIFOX) is safe and effective for adults with pancreatic cancer that has spread to the lining of the belly. Ten participants will receiv…

This early-stage trial is testing a combination of two chemotherapy drugs (melphalan and BCNU) plus vitamins B12b and C, followed by an infusion of the patient's own stem cells. The goal is to see if this approach is safe for people with metastatic pancreatic or breast cancer, es…

This study tests a new drug called WEF-001 in people with advanced solid tumors that have a KRAS mutation, including pancreatic, colorectal, and lung cancers. The goal is to check the drug's safety and how well it shrinks tumors. About 110 adults who have already tried standard t…

This early-phase trial is testing a new drug called OMTX705, which targets a protein on cancer cells, combined with standard chemotherapy and an immunotherapy for people with advanced pancreatic cancer that has spread. The study will enroll 69 participants to first find the safes…

This study compares two types of Whipple surgery for people with pancreatic or nearby cancers: the traditional open surgery and a newer keyhole (laparoscopic) approach. About 90 adults with resectable tumors will be randomly assigned to one of the two procedures. The goal is to s…

This study tests a new drug called HRS-4642 combined with other cancer treatments for people with advanced pancreatic cancer that cannot be removed by surgery. About 60 adults aged 18 to 75 will take part. The goal is to see if the combination is safe and helps control the cancer…

This study looks at how the genetic makeup of pancreatic cancer affects response to a chemotherapy called FOLFIRINOX given before surgery. About 45 adults with non-metastatic pancreatic cancer will receive the chemo, then have their tumors analyzed to see if genetic subtypes (lik…

This phase 2 trial tests an adaptive treatment plan for people with localized pancreatic cancer. Doctors adjust chemotherapy and radiation based on how the tumor responds, aiming to get more patients to successful surgery. The study enrolls 125 adults with resectable or borderlin…

This early-phase study tests a new treatment called IX001 TCR-T for people with advanced pancreatic cancer that has a specific genetic change (KRAS G12V). The treatment uses the patient's own immune cells, which are modified in a lab to better recognize and attack the cancer. The…

This early-stage trial is testing a new drug called DR-0202, a bispecific antibody, in people with advanced solid tumors (such as breast, lung, and pancreatic cancers) that have not responded to at least two prior treatments. The study aims to find a safe dose and see if the drug…

This Phase 2 trial is testing an oral drug called RNK08954 in 60 people with metastatic pancreatic cancer that has a specific genetic change (KRAS G12D mutation). The drug is taken daily and aims to slow tumor growth. Researchers will measure how long the cancer stays under contr…

This trial tests a personalized cell therapy for advanced pancreatic cancer. Patients receive their own immune cells that have been engineered to recognize and attack cancer cells with a specific mutation (KRAS G12V). The study enrolls 30 people whose tumors carry this mutation a…

This trial tests whether giving three treatments together—two medicines and a surgical patch—can lower the risk of major complications after Whipple surgery for pancreatic cancer and other tumors. The study includes 400 high-risk patients with a small pancreatic duct. If successf…

This study tests a new drug called TST001, an antibody that targets a protein called Claudin18.2 found on some cancer cells. It is given alone or with chemotherapy to people with advanced solid tumors that cannot be removed by surgery or have spread. The main goals are to check s…

This study tests whether adding donor natural killer (NK) cells to standard chemotherapy can help prevent cancer from coming back after surgery for pancreatic or bile duct cancer. About 42 adults who had their tumor removed will receive either chemotherapy alone or chemotherapy p…

This study tests a wearable device that creates electric fields (TTFields) combined with chemotherapy for people with metastatic pancreatic cancer. The device is worn at home for at least 18 hours a day and aims to disrupt cancer cell division. The trial will check if the combina…

This early-phase trial tests a new drug called MT-4561 in about 27 people with advanced solid tumors (like lung, breast, or pancreatic cancer) who have no standard options left. The main goals are to find a safe dose and see if the drug can shrink tumors. It is a first-in-human s…

This phase II trial tests a new radiation technique called PULSAR, which delivers short, powerful proton beam pulses every few weeks, adapted to tumor changes. It is for people with locally advanced or limited metastatic pancreatic cancer who have already had some chemotherapy. T…

This study tests a more thorough surgery technique for pancreatic head cancer. The goal is to remove more tissue around the tumor to lower the chance of cancer returning. 90 adults with resectable cancer will be followed for 2 years to see if this approach improves survival and r…

This study tests a new drug (GFH375) combined with either cetuximab or chemotherapy in people with advanced solid tumors that have a specific KRAS G12D mutation. The goal is to see if the combination is safe and can shrink tumors. About 126 adults who have not responded to standa…

This early-phase study tests whether adding a heat-based treatment (radiofrequency ablation) to chemotherapy is safe for people with advanced pancreatic cancer that hasn't spread to other organs. About 15 participants will receive the procedure through an endoscope guided by ultr…

This early-phase study tests a new drug called GV20-0251 in people with advanced solid tumors (like liver, lung, or skin cancer) that have stopped responding to standard therapies. The main goal is to check the drug's safety in a small group of 10 patients. It is not a cure, but …

This study tests whether a sequence of chemotherapy drugs plus two immunotherapy and anti-angiogenesis drugs works better than standard chemotherapy alone for people with advanced pancreatic cancer that cannot be removed by surgery. About 292 participants in China will be randoml…

This phase 2 trial is testing whether adding the drug anakinra (Kineret) to standard chemotherapy can improve outcomes for people with pancreatic cancer that can be surgically removed or is locally advanced. Anakinra is an anti-inflammatory drug typically used for rheumatoid arth…

This early-phase trial tests whether adaptive radiation therapy (ART) can safely deliver higher, more focused radiation doses to pancreatic tumors while protecting nearby organs. Sixteen adults with locally advanced, inoperable pancreatic cancer will receive five treatments over …

This early-stage trial tests a new drug called ProAgio combined with standard chemotherapy (gemcitabine and nab-paclitaxel) in people with advanced pancreatic cancer that has spread. Some participants also get an immunotherapy drug (atezolizumab). The main goals are to find a saf…

This Phase 2 trial is testing whether adding an experimental immunotherapy (TQB2868) and a targeted drug (anlotinib) to standard chemotherapy can help people with pancreatic cancer that has spread. The study will enroll 80 adults who have not had prior treatment. Researchers will…

This phase 3 trial tests whether adding a surgical glue called N-butyl-2-cyanoacrylate to standard pancreatic surgery can prevent postoperative pancreatic fistula—a common and serious leak of digestive fluids. About 194 patients with soft pancreas tissue undergoing tumor removal …

This phase II trial tests a new approach for people with advanced pancreatic cancer that cannot be removed by surgery. Participants first receive standard chemotherapy, then an endoscopic procedure that uses heat to destroy tumor tissue (EUS-RFA), followed by the immunotherapy dr…

This phase 3 trial is testing a new type of PET scan that uses a radioactive tracer called [18F]FAPI-74 to detect whether pancreatic cancer has spread to other parts of the body. About 200 adults with pancreatic cancer will receive one dose of the tracer and then be scanned. The …

This phase 2 study tests whether a radioactive tracer called [68Ga]BED003 can improve PET/CT scans for detecting cancer in the peritoneum (the lining of the abdomen). The trial includes adults with colorectal, ovarian, gastric, pancreatic, or a type of breast cancer. Researchers …

Researchers are testing whether a 3D imaging model called 3D-PANC MSP is better than standard CT scans at showing how pancreatic tumors respond to chemotherapy before surgery. The study includes 70 patients with borderline or locally advanced pancreatic adenocarcinoma who have re…

This study is testing a simple breath test to help detect gastrointestinal cancers—including cancers of the esophagus, stomach, pancreas, liver, and bowel—at an earlier stage. The test measures tiny molecules in exhaled breath that may be linked to these cancers. Participants pro…

This early-phase study is testing two radioactive imaging agents, 68Ga-DFC413 and 68Ga-NNS309, to see how well they highlight tumors on PET scans. About 66 adults with advanced pancreatic, lung, breast, colorectal, or soft tissue cancers will receive the agents. The goal is to co…

This study looks at whether combining special PET and MRI scans with blood tests can detect pancreatic cancer early in people who have pancreatic cysts. The goal is to avoid unnecessary surgery by identifying which cysts are truly dangerous. About 25 adults with high-risk cysts w…

This study tests a new technology called NEO-Match® that measures the stiffness of pancreatic tissue from a biopsy sample. Researchers want to see if this test can predict how well a patient will respond to cancer treatment and help diagnose pancreatic cancer more accurately. Abo…

This study tests a special PET scan that uses a radioactive tracer called 68Ga-FAPI-46 to highlight pancreatic cancer cells. The goal is to see if this scan can find tumors more accurately than current methods. About 130 adults with early-stage pancreatic cancer will get the scan…

This Phase I trial is testing an experimental imaging drug, 203Pb-RMX-VH-PIB, to see how it spreads through the body and how much radiation reaches different organs. The study includes adults with glioblastoma (a type of brain cancer) or pancreatic cancer. Participants receive a …

This study will test a new urine test called Panuri to see how well it can detect pancreatic ductal adenocarcinoma (PDAC), the most common type of pancreatic cancer. About 1100 adults with symptoms that might suggest pancreatic cancer will provide urine samples for analysis. The …

This study is testing a new blood test called PANXEON that looks for tiny genetic particles (miRNAs) to detect pancreatic cancer early. Researchers will collect blood samples from 2,000 people—some with pancreatic cancer and some without—to see how accurate the test is. If it wor…

This study is testing a new blood test that looks at tiny particles called exosomes and their microRNA content, analyzed by machine learning, to detect pancreatic cancer early. It involves 600 people at high risk due to family history or pancreatic cysts. The goal is to see if th…

This study is testing a non-invasive breath test to detect pancreatic cancer earlier. Researchers will collect breath samples from over 6,000 people who have been referred for possible pancreatic cancer. The goal is to see if the test can accurately identify the small number of p…

This study is developing a blood test that looks for tiny genetic molecules called miRNAs, which can signal the presence of several gastrointestinal cancers like liver, pancreatic, and colorectal cancer. Researchers will analyze blood samples from 1,000 adults—half with cancer an…

This study tests a new radioactive tracer called [18F]FPyQCP for PET scans to see if it can better detect several cancers, including colorectal, ovarian, gastric, breast, and pancreatic. About 71 adults with these cancers will receive the tracer and have a PET/CT scan. The goal i…

This study looks for new ways to diagnose pancreatic cancer, a disease that is often caught too late. Researchers will analyze fluid that is normally thrown away after a standard biopsy procedure. They hope to find proteins or other molecules that could lead to a simple blood tes…

This study compares two blood test methods for detecting circulating tumor cells (CTCs) that express a protein called Axl, which is linked to more aggressive cancer. The new technique, called EPIDROP, is being tested against the standard CellSearch method in patients with metasta…

This study is testing a new laser-based blood test that uses nanoparticles to detect pancreatic cancer early. Researchers will enroll 400 people, including those with diabetes, pancreatic cysts, or pancreatic cancer, to see if the test can accurately identify cancer. The goal is …

This study tests a new PET/CT scan using a radioactive tracer called GEH300079 to detect peritoneal carcinomatosis—cancer that has spread to the lining of the abdomen—in people with colorectal, stomach, ovarian, or pancreatic cancer. About 175 adults with known or suspected sprea…

This study aims to see if adding simple blood tests and symptom reviews to standard screening can catch pancreatic cancer earlier in people with a high genetic risk. Researchers will enroll 5,000 participants who have certain gene mutations linked to pancreatic cancer. The goal i…

This study tests whether a new imaging agent called [18F]FAPI-74 can find certain cancers as well as or better than the standard PET tracer. About 320 adults with one of 11 cancer types (including pancreatic, liver, ovarian, and lung cancers) will receive both tracers and have th…

This study aims to develop a non-invasive breath test to detect pancreatic cancer earlier. Pancreatic cancer is often diagnosed late because early symptoms are vague. The test measures tiny molecules in breath that may signal cancer. Researchers will collect breath and urine samp…

This study is testing a software called Lipidica that analyzes fats in the blood to help screen for pancreatic cancer. Researchers will compare results from people with pancreatic cancer to those at high risk (due to family history or genetic factors) to see if the software can t…

This study is testing whether adding an MRI scan to the usual CT scan helps doctors make better decisions about surgery for pancreatic cancer. About 200 patients who are initially thought to be candidates for surgery will be randomly assigned to get either a standard CT alone or …

This study tests a new type of PET scan that uses a tracer called FAPI to see if it can find pancreatic cancer progression or relapse earlier than standard CT or MRI scans. 35 adults with non-spread pancreatic cancer will receive the FAPI-PET scan at several points during their t…

This study is testing a new blood test that looks at fragments of DNA to find pancreatic neuroendocrine tumors early and tell them apart from other pancreatic tumors. Researchers will collect blood from 1,000 adults with different types of pancreatic tumors to see how accurate th…

This study tests a special PET probe called [68Ga]CBP8 to see if it can detect tissue damage caused by radiation therapy in people with lung or pancreatic cancer. About 72 participants will get a PET scan before and 3-6 months after radiation. The goal is to find early signs of r…

This study tests a new type of PET scan that uses a special tracer to light up a protein called FAP, found on pancreatic tumor tissue. The goal is to see if this scan can detect cancer spread that standard CT scans miss. Researchers will compare the new scan with CT in 60 adults …

This study tests whether an MRI scan can detect tiny liver metastases that standard CT scans miss in people with pancreatic cancer. About 120 adults with newly diagnosed pancreatic cancer will get both a CT and an MRI before treatment. If MRI proves better at finding hidden cance…

This study tests an experimental MRI scan that uses a special contrast agent called hyperpolarized carbon-13 pyruvate to see how pancreatic tumors process nutrients. The goal is to find out if this scan can predict treatment response better than standard MRIs. About 70 adults wit…

This study tests an 8-week program of nutrition advice, exercise, and psychological support for people with pancreatic or esophageal cancer before they have surgery. The goal is to see if patients can complete the program and if it helps them prepare for surgery. Only 9 patients …

This study tests whether a remote exercise and nutrition program is practical and acceptable for people with pancreatic cancer who are waiting for surgery. Participants will use a Fitbit, get nutrition advice, and do resistance training at home. The goal is to see if this 'prehab…

This study tests a drug called ponsegromab combined with standard chemotherapy to see if it helps adults with advanced pancreatic cancer who are losing weight and appetite (cachexia). About 982 participants will receive either ponsegromab or a placebo alongside their first chemot…

This study is testing a smartphone app called PDAC-PATHWAYS designed to provide information and support to people with pancreatic cancer who are about to start neoadjuvant therapy (treatment before surgery). The app includes educational modules and tools to help patients cope. Re…

This study tests whether a personalized exercise program given before, during, and after Whipple surgery (a major operation for pancreatic cancer) helps patients recover faster and start chemotherapy sooner. Adults scheduled for Whipple surgery will receive an exercise plan tailo…

This study tests a daily injection called TCMCB07 in 120 people with newly diagnosed colorectal cancer who are starting chemotherapy. The goal is to see if it can help maintain body weight and muscle mass, which often drop during treatment. Participants will receive either the st…

This study is testing an app called PancreasPlus for people with pancreatic cancer. The app helps patients track symptoms, get information, and communicate with their care team from home. Researchers want to see if using the app improves quality of life, reduces anxiety, and cuts…

This study tests a special medical food powder (Encala®) in 18 adults with pancreatic cancer who have trouble absorbing fat, causing stomach issues and weight loss. The goal is to see if the powder is easy to take and helps improve fat absorption and quality of life. This is an e…

This study tests a new nano-formulation of megestrol acetate, a drug used to stimulate appetite and promote weight gain, in patients with advanced pancreatic cancer who suffer from anorexia-cachexia syndrome. The trial will enroll 56 patients and compare those receiving the nano-…

This pilot study is testing whether a structured program of exercise, nutrition counseling, and support—called prehabilitation—can help adults with pancreatic cancer get stronger before surgery. Twenty participants will follow the program while receiving chemotherapy before their…

This study tests whether adding psychosocial (emotional) support to standard prehabilitation helps patients with localized pancreatic cancer during neoadjuvant therapy (chemotherapy/radiation before surgery). Sixty adults will receive nutritional advice, physical therapy, and psy…

This study is testing whether a blood test that looks for tumor DNA (ctDNA) can tell doctors within weeks if chemotherapy is shrinking a patient's pancreatic cancer. Currently, doctors wait about 8 weeks for a scan to see if treatment is working. The trial will enroll 50 people w…

This study aims to find pancreatic cancer earlier in people who are at higher-than-average risk due to family history or genetic mutations. Researchers will collect blood samples and health data from 30,000 participants over time to build a biobank. The goal is to improve early d…

This study looks at whether genetic information from tumors can help doctors choose better treatments for pancreatic cancer. About 200 adults with early or locally advanced pancreatic cancer will receive standard chemotherapy and provide blood, tissue, and fluid samples for genet…

This study is testing a new approach to personalize cancer treatment for people with colorectal or pancreatic cancer. Researchers will take a small sample of a patient's tumor, grow it in the lab, and test different drugs on it to see which one works best. The goal is to see if t…

This study will test if measuring hand grip strength during clinic visits is practical and useful for adults with pancreatic cancer. Fifty participants will squeeze a handheld device and fill out well-being questionnaires alongside their regular care. Researchers want to see if c…

This study looks at genetic changes in metastatic pancreatic cancer to see if they can help guide treatment choices. Researchers will take tumor biopsies and blood samples from 190 patients starting chemotherapy. The main goal is to see if genetic test results can be returned wit…

This early phase trial is testing several targeted drugs in people with pancreatic cancer to see how they affect tumor biology. Researchers will compare tumor samples taken before and after treatment to understand which drugs might work best. The goal is not to treat the cancer d…

This registry is collecting information from 1,500 people with advanced pancreatic cancer in Austria to see how different chemotherapy treatments work in everyday practice. Researchers will track which treatments are used, how well they work, and what side effects occur. The goal…

This study is developing a blood test that looks at tiny genetic particles called microRNAs to predict how well pancreatic cancer will respond to chemotherapy given before surgery. Researchers will collect blood samples from 200 patients with pancreatic cancer who are about to re…

This study collects blood and tumor samples from 100 people with pancreatic cancer who are about to receive standard chemotherapy before surgery. Researchers will use an artificial intelligence algorithm to analyze the tumor tissue and look for biomarkers that predict which treat…

This study is tracking 20,000 people who have a family history of pancreatic cancer or carry genes that raise their risk. Researchers hope to find better ways to detect the disease early, when it's more treatable. Participants will be followed over time to see who develops pancre…

This study investigates whether tiny, lab-grown copies of a patient's own pancreatic tumor—called organoids—can predict how well standard chemotherapy will work. Researchers will collect tumor samples from 164 people with pancreatic cancer, grow organoids from them, and test diff…

This study is testing whether growing a patient's tumor cells in the lab (as 3D 'organoids') can help doctors pick the best drug for advanced cancers that have stopped responding to standard treatments. About 152 adults with colorectal or pancreatic cancer will have a biopsy to c…

This study looks at why people with pancreatic cancer often lose muscle and weight (cachexia). Researchers will collect blood, tissue, and imaging data from 500 patients to understand the biology and build an AI model that could warn doctors early. It is an observational study, s…

This study is testing a new technique called EXPEL to find biomarkers for pancreatic cancer. Researchers will analyze the fluid used to preserve biopsy samples from 200 patients with suspected pancreatic cancer. The goal is to identify proteins and other molecules that could help…

This study explores whether a special MRI technique called 3D-MRE can measure the stiffness of pancreatic tumors to help predict how the disease will progress. Researchers will enroll 200 adults with pancreatic cancer and compare imaging results with actual tumor hardness and tre…

This study looks at how obesity might help cause pancreatic cancer, especially in African American and non-Hispanic White people. Researchers will compare tumors and fat tissue from 125 adults to find differences that could lead to better treatments. The goal is to understand why…

This study looks at how pancreatic cancer cells get and use nutrients to grow. Researchers will give a special sugar to 16 patients during surgery to trace the cancer's energy use in the lab. The goal is to find weaknesses in the cancer's fuel system that could lead to new treatm…

This observational study tracks 80 people with advanced pancreatic cancer that has a specific genetic change called KRAS G12R. Participants receive one of three treatment plans: a MEK inhibitor combined with other drugs, with or without hydroxychloroquine or an EGFR inhibitor. Th…

This pilot study aims to see if using five gene signatures from a patient's tumor can help doctors choose the best first chemotherapy for advanced pancreatic cancer. About 85 people with metastatic pancreatic cancer will have their tumor genes analyzed to pick between two standar…

This study is for people at high risk of pancreatic cancer, such as those with a strong family history or certain genetic conditions. Researchers will use MRI and endoscopic ultrasound to screen participants regularly and see which method works best. The goal is to detect cancer …

This study aims to grow miniature versions of pancreatic tumors, called organoids, from small biopsy samples taken during routine endoscopic procedures. Researchers will check if these organoids match the genetic makeup of the original tumor. If successful, this approach could al…

This study looks at tiny molecules called microRNA in the blood of people with advanced pancreatic cancer. Researchers want to see if these molecules can help diagnose the disease earlier, predict how it will progress, and show whether treatment is working. The study will follow …

This study aims to understand why liver metastases are so deadly in colorectal and pancreatic cancers. Researchers will analyze tumors and blood from 625 participants to find new targets for immune and gene therapies. The goal is to develop better treatments for these hard-to-tre…

This study looks at whether a blood marker called mHLA-DR can help doctors predict severe complications after pancreatic surgery. About 100 people having this surgery will be followed. The goal is to find an early warning sign for problems like infection or pancreatic leaks.

This study looks at the genes of 750 people with advanced or metastatic pancreatic cancer. The goal is to find specific genetic changes that could help doctors choose better treatments, like targeted drugs or chemotherapy combinations. Participants must have a tumor sample availa…

This study tests a new screening program for people aged 50 to 85 who have recently developed diabetes and are at high risk for pancreatic cancer. Participants will receive repeated AI-enhanced CT scans and blood draws over time to see if these tools can spot cancer earlier than …

This study looks at whether a simple blood test can find tiny bits of tumor DNA (ctDNA and eccDNA) in people with pancreatic cancer that can be surgically removed. The goal is to see if these tests can predict if the cancer will come back early and help doctors monitor patients m…

This early phase 1 trial is studying how the drug OMO-103 affects pancreatic cancer cells in 12 patients with advanced or metastatic pancreatic ductal adenocarcinoma. The main goal is to see if the drug changes the tumor's biology by analyzing tissue samples before and after trea…

This study is testing whether a simple rectal mucus sample can detect DNA changes linked to lung, pancreatic, bladder, and colorectal cancers. Researchers will collect samples from 450 adults using a special device and analyze them for genetic and epigenetic markers. The goal is …

This study enrolls 5,000 people at high risk for pancreatic cancer to donate blood, pancreatic juice, and medical images over 10 years. Researchers will use this information to develop and validate tests that can detect pancreatic cancer earlier, when it may be more treatable. Pa…

This study explores whether a special MRI technique called 3D magnetic resonance elastography (MRE) can accurately measure the stiffness of pancreatic tumors and surrounding scar tissue. Researchers will enroll 200 adults with pancreatic cancer to see if these stiffness measureme…

This study looks at tiny particles called exosomes, which carry proteins and genetic material between cells. Researchers will collect blood and tissue from 181 people with pancreatic cancer or noncancerous pancreatic disease to compare exosome activity. The goal is to understand …

This study looks at how pancreatic cancer changes over time in people receiving chemotherapy. Researchers take small tissue samples from the tumor at diagnosis and again after treatment to see if the cancer's genetic type has shifted. The goal is to better understand how the canc…

This study will follow 3,000 pancreatic cancer patients in China who are receiving irinotecan liposome II as part of their treatment. Researchers will collect data on side effects, survival, and how well the drug controls the cancer. The goal is to understand how this treatment w…

This study is testing whether a special type of ultrasound called multiparametric ultrasound (mpUS) can provide more detailed images of tissue than standard ultrasound. Researchers will compare mpUS results with regular tests in up to 85 people who are at high risk for pancreatic…

This study follows 4,000 adults aged 30 and older who have at least one pancreatic cyst, a common finding on scans. Researchers will track changes over time using surveys and medical records to see which cysts turn into cancer. The goal is to better tell harmless cysts from dange…

This study is looking for biological markers in the blood and tissue that can tell apart harmless pancreatic cysts (IPMN) from those that are likely to turn into pancreatic cancer. Researchers will follow 3,600 patients with IPMN across four Italian hospitals, collecting blood sa…